Search - tctmd.com

Displaying 301 - 320 of 375

Sort: Relevancy | Date

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

Presentation TCT 2014

Postprocedural/Prehemostasis Intraarterial Nitroglycerin: A Prospective, Randomized Trial Evaluating Intrasheath Nitroglycerin to Improve Arterial Patency After Transradial Catheterization

Presenter: Steven R. Bailey, Surya Dharma

September 14, 2014

Presentation TCT 2014

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Presenter: Paul A. Gurbel, Dmitriy N. Feldman

September 14, 2014

Presentation

Aspirin Treatment and Outcomes After PCI

Presenter: Katharina Mayer

August 25, 2014

Presentation

Contemporary Patterns of Discharge Aspirin Dosing After Acute MI in the United States

Presenter: H.M. Hall

August 13, 2014

Presentation PCI Outcomes 2014

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Presenter: Christopher Granger

March 28, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Presentation TCT 2013

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation

Pharmacology in High-Risk PCI: Focus on Clinical Outcomes

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

EUROMAX: Critical Appraisal and Clinical Implications

Presenter: Gregg Stone

October 30, 2013

Presentation TCT 2013

The Ongoing Saga of Short DAPT Therapy After DES: Navigating Device Evolution, New Pharmacotherapy, and Changing Clinical Practice Standards

Presenter: Roxana Mehran

October 30, 2013

Presentation TCT 2013

Expanding Clinical Indications: Moderate Hypertension and Replacing (vs. Supplementing) Medical Pharmacotherapy

Presenter: Krishna Rocha-Singh

October 30, 2013

Presentation TCT 2013

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Presenter: Dmitriy Feldman

October 28, 2013

Presentation

Duration of Dual Antiplatelet Treatment with Clopidogrel and Aspirin in Patients with ACS

Presenter: Christoph Varenhorst

October 18, 2013

Advertisement

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Postprocedural/Prehemostasis Intraarterial Nitroglycerin: A Prospective, Randomized Trial Evaluating Intrasheath Nitroglycerin to Improve Arterial Patency After Transradial Catheterization

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Aspirin Treatment and Outcomes After PCI

Contemporary Patterns of Discharge Aspirin Dosing After Acute MI in the United States

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

Genetic Testing is of Clear Clinical Utility in Selected Patients

Critical Appraisal and Clinical Implications(3)

Pharmacology in High-Risk PCI: Focus on Clinical Outcomes

EUROMAX: Critical Appraisal and Clinical Implications

The Ongoing Saga of Short DAPT Therapy After DES: Navigating Device Evolution, New Pharmacotherapy, and Changing Clinical Practice Standards

Expanding Clinical Indications: Moderate Hypertension and Replacing (vs. Supplementing) Medical Pharmacotherapy

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Duration of Dual Antiplatelet Treatment with Clopidogrel and Aspirin in Patients with ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content